Elacestrant combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC): Preliminary data from ELEVATE, a phase Ib/II, open-label, umbrella study

被引：1
|
作者：
Rugo, H. S. [1 ]
O'Shaughnessy, J. [2 ]
Cortes, J. [3 ]
Bardia, A. [4 ]
Hamilton, E. P. [5 ]
Hurvitz, S. A. [6 ]
Kaklamani, V. [7 ]
Mchayleh, W. [8 ]
Romero, P. Munoz [9 ]
Vallespir, B. Piza [10 ]
Wasserman, T. [11 ]
Theall, K. P. [12 ]
Tolaney, S. M. [13 ]
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, Breast Dept, San Francisco, CA USA
[2] Baylor Univ, Med Ctr, Texas Oncol, Med Oncol Dept,US Oncol, Dallas, TX USA
[3] Quironsalud Grp, Int Breast Canc Ctr IBCC, Med Oncol Dept, Barcelona, Spain
[4] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Univ Calif Los Angeles UCLA Hlth, Med Oncol Dept, Los Angeles, CA 90024 USA
[5] Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA
[6] Univ Washington, Fred Hutchinson Canc Ctr, Med Hematol Oncol Dept, Seattle, CA USA
[7] Univ Texas Hlth Sci Ctr San Antonio, Med Oncol Dept, San Antonio, TX 78229 USA
[8] AdventHlth Canc Inst, Oncol, Orlando, FL USA
[9] Menarini Grp, Biostat & Data Management Dept, Florence, Italy
[10] Menarini Grp, Clin Sci Dept, Florence, Italy
[11] Menarini Grp, Global Med Affairs Dept, Florence, Italy
[12] Menarini Grp, Global Prod Dev Dept, New York, NY USA
[13] Dana Farber Canc Inst, Med Oncol Dept, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.317
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
369P
引用
收藏
页码：S372 / S373
页数：2
相关论文
共 50 条
  • [21] ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in women and men with metastatic breast cancer (mBC)
    Rugo, Hope
    Bardia, Aditya
    Cortes, Javier
    Curigliano, Giuseppe
    Hamilton, Erika
    Hurvitz, Sara
    Loibl, Sibylle
    Scartoni, Simona
    Sahmoud, Tarek
    Grzegorzewski, Krzysztof
    Habboubi, Nassir
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2023, 83 (05)
  • [22] Pharmacokinetics of H3B-6545 in patients with locally advanced or metastatic estrogen receptor-positive HER2 negative breast cancer (ER+ and HER2-BC)
    Majid, Oneeb
    Xiao, Jianjun Alan
    Sahmoud, Tarek
    Yasuda, Sanae
    Cantagallo, Lisa
    Hamilton, Erika P.
    Pluard, Timothy
    Juric, Dejan
    Gualberto, Antonio
    Husseiin, Ziad
    CANCER RESEARCH, 2021, 81 (04)
  • [23] A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer
    Jhaveri, Komal
    Winer, Eric Paul
    Lim, Elgene
    Fidalgo, Jose AlejandroPerez
    Bellet, Meritxell
    Mayer, Ingrid Alina
    Boni, Valentina
    Patel, Jaymin M.
    Bardia, Aditya
    Garcia, Jose Manuel
    Kabos, Peter
    Gates, Mary
    Chen, Ya-Chi
    Fredrickson, Jill
    Wang, Xiaojing
    Friedman, Lori Sickels
    Spoerke, Jill
    Gendreau, Steven
    Metcalfe, Ciara
    Liu, Lichuan
    Chang, Ching-Wei
    Monemi, Sharareh
    Gonzalez, Monica
    McCurry, Ursula
    Milan, Sandra
    Humke, Eric William
    Loi, Sherene
    CANCER RESEARCH, 2020, 80 (04)
  • [24] A phase II open label study of everolimus in combination with antiestrogen therapy in hormone receptor-positive HER2-negative advanced breast cancer
    Yardley, Denise A.
    Shastry, Mythili
    DeBusk, Laura M.
    Burris, Howard A., III
    Hainsworth, John D.
    CANCER RESEARCH, 2015, 75
  • [25] A Multicenter, Phase Ib/II Study of Abemaciclib in Combination with Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
    Casasanta, Nicole
    Landry, Chrystal
    Shao, Theresa
    Klein, Paula
    Fasano, Julie
    Bhardwaj, Aarti
    Berger, Natalie
    Moshier, Erin
    Joshi, Gargi Atul
    Vaccaro, Rita
    Sparano, Joseph
    Tiersten, Amy
    CANCER RESEARCH, 2024, 84 (09)
  • [26] Interim analyses (IA) of the giredestrant (G), G plus abemaciclib (A), and G plus ribociclib (R) arms in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced/metastatic BC (ER+, HER2-LA/mBC).
    Oliveira, Mafalda
    Sonnenblick, Amir
    Rugo, Hope S.
    Jung, Kyung Hae
    Yam, Einav Gal
    Hurvitz, Sara A.
    Hernando, Cristina
    Im, Seock-Ah
    Breton, Vanessa
    Collier, Ann
    Schwab, Richard B.
    Zhu, Jing
    Sohn, Joohyuk
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] Interim analysis (IA) of the giredestrant (G) plus ipatasertib (IPAT) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/ metastatic BC (LA/mBC)
    Jung, K. H.
    Luen, S. J.
    Oliveira, M.
    Sohn, J.
    Im, S-A.
    Wander, S.
    Hurvitz, S. A.
    Sonnenblick, A.
    Breton, V.
    Collier, A.
    Deb, S.
    Ngo, H.
    Schwab, R.
    Shemesh, C.
    Zhu, J.
    Hernando Melia, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S347 - S347
  • [28] Interim analysis (IA) of the giredestrant (G) plus samuraciclib (SAMURA) arm in MORPHEUS breast cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)
    Oliveira, M.
    Gion Cortes, M.
    Jung, K. H.
    Bermejo, B.
    Hurvitz, S. A.
    Sadeghi, S.
    Wander, S.
    Im, S-A.
    Gal-Yam, E.
    Zhu, J.
    Schwab, R.
    Ngo, H.
    Collier, A.
    Cannon, M.
    Cahuzac, C.
    Moreno, P. D. Perez
    Mcintosh, S.
    Saavedra Serrano, C.
    Sonnenblick, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S370 - S371
  • [29] The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study
    Lim, Elgene
    Boyle, Frances
    Okera, Meena
    Loi, Sherene
    Goksu, Sema Sezgin
    van Hal, Gertjan
    Hartman, Daisy G.
    Gable, Jonathon Colby
    Price, Gregory L.
    Hossain, Anwar
    Gainford, M. C.
    Ezquerra, Meritxell Bellet
    CANCER RESEARCH, 2020, 80 (04)
  • [30] H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (-) breast cancer (BC)
    Hamilton, Erika P.
    Pluard, Timothy J.
    Wang, Judy S.
    Morikawa, Aki
    Johnston, Stephen R. D.
    Dees, Elizabeth Claire
    Vaklavas, Christos
    Armstrong, Anne C.
    Munster, Pamela N.
    Unni, Nisha
    Wright, Gail Lynn Shaw
    Kayali, Fadi
    Song, Tingting
    Rong, Yuanxin
    Yamaguchi, Kohei
    Juric, Dejan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345